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Abstract
Objectives. Patients with SSc have an increased risk of malignancy compared with the general popula-
tion. Before now, no study has evaluated the risk of thyroid cancer (TC) in SSc patients. The aim of the
study was to evaluate the prevalence of TC in SSc patients.
Methods. We studied the prevalence of TC in 327 unselected SSc patients in comparison with two
population-based, gender- and age-matched control groups (654 subjects from an iodine-deficient area
and 654 subjects from an iodine-sufficient area). Thyroid status was assessed by measurement of circu-
lating thyroid hormones and autoantibodies, thyroid ultrasonography and fine-needle aspiration cytology
(when necessary).
Results. Circulating thyroid-stimulating hormone, anti-thyroglobulin and anti-thyroperoxidase antibody
levels, and the prevalence of hypothyroidism were significantly higher in SSc patients (P<0.01, for all).
Six patients with papillary TC (PTC) were detected among SSc patients, whereas only one case was
observed in each of controls 1 and 2 (P = 0.007, for both). In SSc all patients with TC had evidence of
thyroid autoimmunity vs 40% of the other SSc patients (P = 0.001).
Conclusion. These data suggest a high prevalence of papillary TC in SSc patients, in particular in the
presence of thyroid autoimmunity; careful thyroid monitoring would be opportune during the follow-up of
these patients.
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Rheumatology key messages
. Papillary thyroid cancer is predominantly observed in SSc patients with respect to iodine-deficient and iodine-
sufficient controls.
. All SSc patients with papillary thyroid cancer have thyroid autoimmunity, vs 40% of other SSc patients.
. A careful thyroid evaluation should be carried out during the follow-up of SSc patients.
Introduction
Patients with SSc may have an increased risk of malig-
nancy compared with the general population [1]. A wide
array of cancers has been reported in scleroderma,
although lung and breast cancers are thought to be the
most common [2].
Papillary thyroid cancer (PTC) presents most commonly
between 30 and 50 years of age, with a preponderance of
female/male = 3:1. Radiation exposure is a risk factor for
PTC [3]. The prevalence of PTC is higher where iodine
intake is excessive, or in case of iodine prophylaxis [4].
A longitudinal follow-up study has shown a high inci-
dence of new cases of hypothyroidism and thyroid dys-
function in female sclerodermic patients, suggesting that
the ones who are at high risk [those with a borderline high
(even if in the normal range) thyroid-stimulating hormone
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(TSH) value, anti-thyroperoxidase antibody (AbTPO) posi-
tivity and a hypoechoic and small thyroid] should have
periodic thyroid function follow-up [5].
A few studies have reported sporadic cases of PTC in
patients with SSc [6, 7].
The present (casecontrol) study prospectively investi-
gated prevalence and features of thyroid cancer (TC) in a
large series of unselected patients with SSc in comparison
with two matched samples from the general population




A total of 327 SSc patients consecutively referred to the
Rheumatology Units of the University of Pisa and Modena
(from 1995 to 2009) were recruited into the study. SSc
was classified according to the ACR 1980 preliminary
criteria [8]. Standardized criteria were followed for the
evaluation of clinico-serological features, main visceral
organ involvement and disease activity [9]. In SSc pa-
tients, disease duration ranged from 7 to 112 months;
skin sclerosis was observed in all patients (diffuse 52%
or limited 48%); visceral involvement included: peripheral
vascular system, 94%; gastrointestinal system, 51%;
lung, 64%; joint/tendons, 21%; heart, 35%; kidney, 9%.
The prevalence of autoantibodies, evaluated according to
standard methodologies [9], was: antinuclear 91% (with
nucleolar pattern 24%), anti-centromere 37%, anti-topo I
(anti-Scl-70) 41%.
Controls
Since iodine intake differs within Tuscany, and reliable
data on local iodine intake based on urinary iodine excre-
tion are available, two different control groups were used.
The first group consisted of controls from an iodine-
deficient area. Among 3124 subjects randomly extracted
from the general registry of North-West Tuscany and sys-
tematically screened for thyroid disorders, two individuals
of same gender and similar age (± 5 years of age), for each
SSc patient, were randomly selected and used as a popu-
lation-based, gender- and age-matched control group
(Table 1). The majority (87%) of these control subjects
had resided in an iodine-deficient area for 20 years or
more, which was considered a criterion of historical
iodine deficiency.
The second group consisted of controls from an iodine-
sufficient area. This control group was obtained choosing
two individuals of same gender and similar age (± 5 years
of age), for each SSc patient, who were randomly ex-
tracted from the background population of an area of
iodine sufficiency (central Tuscany) who had been
screened for thyroid disorders. Among these control sub-
jects, 19% had resided in an iodine-deficient area for 20
years or more (Table 1). Control subjects with previous
radiotherapy were excluded. All patients and controls
gave informed consent for the study, which was approved
by the Institutional Ethics Committee (Comitato Etico di
Area Vasta Nord-Ovest).
All patients and controls underwent a complete clinical
evaluation (Table 1) and were prospectively evaluated with
respect to TSH, free thyroxine (FT4), free triiodothyronine
(FT3), anti-thyroglobulin antibody (AbTg), AbTPO deter-
mination and physical examination, thyroid US, and fine-
needle aspiration (FNA) (if necessary).
US of the neck and FNA
Neck US and FNA were performed as previously reported
[3]. FNA was performed in palpable nodules; nodules that
were not palpable were examined by FNA only when clin-
ical findings or the echographic pattern [10, 11] suggested
the opportunity of excluding malignancy (>8 mm, solid
hypoechoic appearance, and/or irregular or blurred mar-
gins, and/or microcalcifications) [12].
Laboratory evaluation
Serum levels of TSH (DiaSorin, USA; reference range
0.33.6 mIU/l), FT3 and FT4 (AMERLEX-MAB FT3/FT4
Kit; Amersham, Little Chalfont, UK), AbTPO and AbTg
(ICN Pharmaceuticals, USA; positivity was set at >100
kIU/l) were evaluated.
Statistical analysis
Data are expressed as mean (S.D.). For continuous vari-
ables, group differences were tested by analysis of vari-
ance; when this was significant at the P40.05 level,
between-group comparisons were carried out by the
BonferroniDunn test. Group differences were tested for
categorical variables, by Fisher’s Exact test (two-tailed).
Furthermore, the odds ratio was used when at least one
case of thyroid disorder was observed in the controls. A
P< 0.05 was considered significant. We used StatView
software, Version 5.0, SAS Institute Inc., SAS Campus
Drive, Cary NC 27513, USA, for statistical analysis.
Results
The samples had similar distributions by gender, age
(by selection criteria) and smoking habits (Table 1). A posi-
tive family history of thyroid disease was significantly
more frequent in controls from the iodine-deficient area
and in SSc patients than in controls from the iodine-
sufficient area.
In SSc patients, serum TSH levels, AbTg and AbTPO
titres were significantly higher, whereas FT3 and FT4 were
significantly lower in comparison with the other groups
(Table 1).
Hypothyroidism (defined as a TSH level >4 mIU/l, in the
presence of normal or low values of FT3 and/or FT4) was
significantly more common in SSc patients than in the
other groups. The prevalence of subclinical and clinical
hyperthyroidism (defined as a TSH level <0.3 mIU/l, in
the presence of normal or high values of FT3 and/or
FT4) was not significantly higher in SSc patients (Table
1). Non-thyroidal illness syndrome [defined as low serum
FT3, normal to low FT4, high reverse T3 (ranging from 1.08
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to 2.46 nmol/l) and normal TSH] was observed in 3% of
SSc patients.
The prevalence of thyroid nodules was higher in control
subjects from the iodine-deficient area and in SSc
patients than in the controls from the iodine-sufficient
area (Table 1). FNA was performed in 14% of SSc patients
[57 nodules in 46 patients were biopsied, 1.2 (mean) nod-
ules biopsied (range 12) per patient receiving FNA;
median nodule size was 19 mm], in 13% of iodine-
deficient controls [108 nodules biopsied in 85 patients,
1.3 (mean) nodules biopsied (range 13) for each patient
submitted to FNA; median nodule size, 21 mm] and 9% of
iodine-sufficient controls [77 nodules biopsied in 59
patients, 1.3 (mean) nodules biopsied (range 12) per
patient submitted to FNA; median nodule size, 18 mm].
Following standard criteria [13], the cytological samples
were subdivided into classes: class 1, macrophages and
colloid with no or rare follicular cells; class 2, benign
nodule; class 3, indeterminate follicular lesion; class 4,
suspect or frankly malignant. The distributions of cytolo-
gical results in SSc, iodine-deficient and iodine-
sufficient groups were: class 1 (7, 8, 8%, respectively);
class 2 (82, 85, 86%, respectively); class 3 (4, 7, 8%, re-
spectively). No significant differences in the distribution of
classes 1, 2 and 3 results between the three groups were
observed (2, P = 0.9).
Four class 4 (7%) suspect or frankly malignant cytolo-
gical results were observed in SSc patients. This class of
results was only observed in the SSc group.
Thyroidectomy was performed in all patients and controls
with class 3 cytology; upon histological examination, a
PTC was found in two SSc patients and in one subject
from each control group. In the four SSc patients with
class 4 cytology, post-thyroidectomy histological examin-
ation revealed PTC.
To sum up, six PTCs were detected in the SSc series,
while only one case was observed in each control group
(Table 1) [P = 0.007, by Fisher’s Exact test (two-tailed) P-
value, for SSc vs each control group]. The size of nodules
with cancer, at histological examination, varied from 8 to
43 mm (median 19 mm). The TNM Classification of
Malignant Tumours stage [14] was T1 in three, T2 in two
and T3 in one of the PTC patients; no case of lymph node
or distant metastasis was detected.
The V600EBRAF mutation was observed in one of the
three patients evaluated. No other endocrine neoplasias
were found in SSc patients.
The odds ratio for PTC was significantly higher in SSc
patients than in iodine-sufficient controls (odds
ratio = 12.2; 95% CI: 1.9, 77.4).
SSc patients with PTC did not differ from the other SSc
patients (Table 2) in terms of gender distribution (M/F: 1/5,
27/294; respectively), age [54 (12), 55 (11), years; respect-
ively], serum TSH [TSH in non-nodule-SSc, in benign-
nodule-SSc and in PTC-SSc were, 3.5 (95% CI: 0.01,
51.4), 2.9 (95% CI: 0.01, 11.2) and 3.1 (95% CI: 0.4,
6.7), respectively; P = ns], FT3, FT4, AbTg or AbTPO con-
centrations. Five SSc patients with PTC had positive
circulating thyroid autoantibodies (AbTg titre: 11, 28, 42,
191, 641, 823 kIU/l, respectively; AbTPO titre: 11, 109,
122, 218, 292, 713 kIU/l, respectively) at the time of sur-
gery, and three had PTC in the context of chronic thyroi-
ditis on histological examination. Altogether, all SSc
patients with PTC had evidence of thyroid autoimmunity
(6 vs 0), whereas only 40% (128 vs 193) (Fisher’s Exact
test P = 0.004) of SSc patients without TC exhibited
TABLE 1 Clinical characteristics and comparison of thyroid status between patients with SSc and controls
Data Controls (iodine deficient) SSc Controls (iodine sufficient) P-value
n 654 327 654
Age, mean (S.D.), years 55 (11) 54 (14) 54 (13) 0.724
Men/women, % 8/92 8/92 8/92 1
Iodine deficiency, % 87a,d 57a,e,f 19 <0.0001
Familial thyroid disease, % 46a,d 38a,e 18 <0.0001
Smokers, % 22 21 24 0.526
TSH, median (range), mIU/l 1.2 (0.018.7) 3.2 (0.0151.4)b,e,f 1.4 (0.19.6) 0.0013
FT4, mean (S.D.), pmol/l 11.4 (3.1) 9.5 (5.1)b,d,f 12.2 (2.9) 0.537
FT3, mean (S.D.), pmol/l 5.1 (1.5) 4.6 (1.6)b,d,f 4.9 (2.1) 0.421
AbTg, median (range), kIU/l 31 (3321) 135 (21213)b,d,f 47 (1476) 0.041
AbTPO, median (range), kIU/l 29 (1423) 115 (92132)b,d,f 28 (4432) 0.0005
AbTg+, % 8 18b,d,f 12 0.0001
AbTPO+, % 7 35b,d,f 9 0.0001
Hypothyroidism, TSH >4 mIU/l, % 3 20c,e,f 5 <0.0001
Hyperthyroidism, TSH <0.3 mIU/l, % 3 4 2 0.172
Thyroid nodules, % 25 (163/491) 28 (91/236) 15 (98/556)c,d <0.0001
0.26 vs iod def
Papillary thyroid cancer, n 1 6e,f 1 0.007
aP< 0.05 by 2. bP4 0.05 by the BonferroniDunn test or MannWhitney U test (for TSH, AbTg, AbTPO). cP<0.05 by 2, or
by Fisher’s Exact test. dIodine deficient vs iodine sufficient. eSSc vs iodine sufficient. fSSc vs iodine deficient. AbTg: anti-
thyroglobulin antibody; AbTPO: anti-thyroperoxidase antibody; FT3: free triiodothyronine; FT4: free thyroxine; TSH: thyroid-
stimulating hormone; n: number.
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evidence of thyroid autoimmunity (Table 2). The presence
of PTC was not associated with any specific SSc treat-
ment, or duration of the disease.
Discussion
This study is the first to show that PTC is observed with
higher prevalence in SSc patients than in age- and
gender-matched iodine-deficient controls, and iodine-
sufficient controls. To eliminate bias in the observed
prevalence of TC due to differences in iodine uptake, con-
trol groups from both high- and low-iodine-intake regions
were used [4]. The results show a significantly higher
prevalence of PTC in SSc patients than in either control
group. The low prevalence of PTC in the control groups is
in agreement with the low prevalence of TC (1/1411 sub-
jects screened) recently reported from a population-based
study in Southern Italy [10]. However, we cannot com-
pletely rule out that surveillance bias may be a possible
explanation for finding more cancers in the cases than in
controls undergoing routine screening.
The mechanisms connecting SSc and malignancies are
unknown. The occurrence of different cancer types in asso-
ciation with SSc or SSc-like disorders suggests a range of
underlying mechanisms, including altered immune response,
common genetic and environmental links, disease-
dependent factors, tumour-derived biologic substances
and therapies [2]. The process of sclerosis itself may favour
cancer in certain sites, such as lung and breast [2].
In our patients, autoimmune thyroid involvement and
hypothyroidism were more frequently observed in patients
with SSc than in the comparison groups, in agreement
with results from other studies [15, 16]. An association
between TC and chronic thyroiditis has been observed
in many studies [17, 18].
In our study, features of thyroid autoimmunity were
observed in all SSc patients with PTC, in comparison with
its occurrence in 40% of SSc patients without TC, reinfor-
cing the hypothesis that thyroid autoimmunity may be a
predisposing condition for PTC. In our SSc patients, TSH
was higher in the SSc group than in controls, and it is
known that nodules are statistically more often malignant
in patients with higher TSH [19]. Even though TSH levels in
non-nodule-SSc, in benign-nodule-SSc and in PTC-SSc
were not significantly different, we cannot exclude the pos-
sibility that a high TSH could be associated with PTC in SSc.
Another hypothesis proposed to explain the increase in
cancers in SSc patients is the exposure to medications [2].
However, the presence of PTC was not associated with any
specific treatment of SSc in our series. Furthermore, no spe-
cific treatment of SSc is known to be associated with TC.
Whether the B-Raf proto-oncogene, serine/threonine
kinase (BRAF)-Mitogen-Activated Protein Kinase (MEK)-
extracellular signal-regulated kinases (ERK) pathway acti-
vation plays a common role in PTC and SSc remains to be
investigated; however, we have found the V600EBRAF mu-
tation was observed in one among three patients evalu-
ated, in line with the frequency observed in PTC patients
without SSc [20].
In conclusion, this study is the first to show an increased
risk of PTC in SSc patients, and an association with thyroid
autoimmunity. As such, we recommend that careful thyroid
evaluation (by US, FT4, TSH, AbTPO measurements) should
be carried out during the follow-up of these patients.
Funding: No specific funding was received from any fund-
ing bodies in the public, commercial or not-for-profit sec-
tors to carry out the work described in this manuscript.
Disclosure statement: The authors have declared no
conflicts of interest.
References
1 Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of
cancer in patients with scleroderma: a population based
cohort study. Ann Rheum Dis 2003;62:72831.
2 Bonifazi M, Tramacere I, Pomponio G et al. Systemic
sclerosis (scleroderma) and cancer risk: systematic review
and meta-analysis of observational studies.
Rheumatology 2013;52:14354.
3 Antonelli A, Miccoli P, Derzhitski VE et al. Epidemiologic
and clinical evaluation of thyroid cancer in children from
the Gomel region (Belarus). World J Surg 1996;20:86771.
4 Smyth P, Cloughley G, Clarke C et al. Iodine and differ-
entiated thyroid cancer: pathogenetic and therapeutic
implications. Hormones 2009;8:1928.
5 Antonelli A, Fallahi P, Ferrari SM et al. Incidence of thyroid
disorders in systemic sclerosis: results from a longitudinal
follow-up. J Clin Endocrinol Metab 2013;98:E1198202.
6 Gokula RM, Gupta AK, Shirley SE, Coard K, Ramphal PS.
Scleroderma with cardiac tamponade, hyperthyroidism
and incidental papillary thyroid carcinoma. West Indian
Med J 2002;51:18890.
7 Antonelli A, Ferri C, Fallahi P et al. Clinical and subclinical
autoimmune thyroid disorders in systemic sclerosis. Eur J
Endocrinol 2007;156:4317.
8 Subcommittee for Scleroderma Criteria of the American
Rheumatism Association Diagnostic and Therapeutic
Committee. Preliminary criteria for the classification of
systemic sclerosis (scleroderma). Arthritis Rheum
1980;23:58190.
TABLE 2 Clinical and laboratory data in SSc patients with
(CA-SSc) or without papillary thyroid cancer (SSc)
SSc CA-SSc P-value
Total, n 321 6
Age, mean (S.D.), years 55 (11) 54 (12) 0.675a
Men/women, n 27/294 1/5 0.418b
Diffuse/limited, n 168/153 2/4 0.432b
Anti-antinuclear Ab (±), n 293/28 5/1 0.429b
Anti-centromere Ab (±), n 119/202 2/4 >0.999b
Anti-topo I Ab(±), n 130/191 2/4 >0.999b
AbTg (±), n 59/262 3/3 0.084b
AbTPO (±), n 109/212 5/1 0.021b
aANOVA; bFishers’s Exact test P-value. n: number.
www.rheumatology.oxfordjournals.org 483







atology/article/55/3/480/1793373 by guest on 13 N
ovem
ber 2020
9 Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis:
demographic, clinical and serologic features and survival
in 1,012 Italian patients. Medicine 2002;8:13953.
10 Aghini-Lombardi F, Antonangeli L, Martino E et al. The
spectrum of thyroid disorders in an iodine-deficient com-
munity: the Pescopagano survey. J Clin Endocrinol Metab
1999;84:5616.
11 Antonelli A, Miccoli P, Fallahi P et al. Role of neck ultra-
sonography in the follow-up of children operated on for
thyroid papillary cancer. Thyroid 2003;13:47984.
12 Papini E, Guglielmi R, Bianchini A et al. Risk of malignancy
in nonpalpable thyroid nodules: predictive value of ultra-
sound and color-Doppler features. J Clin Endocrinol
Metab 2002;87:19416.
13 Baloch ZW, Sack MJ, Yu GH, Livolsi VA, Gupta PK. Fine-
needle aspiration of thyroid: an institutional experience.
Thyroid 1998;8:5659.
14 NCCN Clinical Practice Guidelines in Oncology: Thyroid
Carcinoma. V.2.2013. http://www.nccn.org/professionals/
physician_gls/pdf/thyroid.pdf (5 September, 2013, date
last accessed)
15 Molteni M, Barili M, Eisera N et al. Anti-thyroid antibodies
in Italian scleroderma patients: association of anti-thyroid
peroxidase (anti-TPO) antibodies with HLA-DR15. Clin
Exp Rheumatol 1997;15:52934.
16 Antonelli A, Ferri C, Fallahi P et al. Th1 and Th2 chemokine
serum levels in systemic sclerosis in the presence or
absence of autoimmune thyroiditis. J Rheumatol
2008;35:180911.
17 Boi F, Lai ML, Marziani B et al. High prevalence of suspi-
cious cytology in thyroid nodules associated with positive
thyroid autoantibodies. Eur J Endocrinol
2005;153:63742.
18 Antonelli A, Mosca M, Fallahi P et al. Thyroid cancer in
systemic lupus erythematosus: a casecontrol study.
J Clin Endocrinol Metab 2010;95:3148.
19 Fiore E, Vitti P. Serum TSH and risk of papillary thyroid
cancer in nodular thyroid disease. J Clin Endocrinol Metab
2012;97:113445.
20 Antonelli A, Fallahi P, Ferrari SM et al. RET TKI: poten-
tial role in thyroid cancers. Curr Oncol Rep
2012;14:97104.
484 www.rheumatology.oxfordjournals.org







atology/article/55/3/480/1793373 by guest on 13 N
ovem
ber 2020
